Anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of MC21-B, an antibacterial compound produced by the marine bacterium Pseudoalteromonas phenolica O-BC30T

International Journal of Antimicrobial Agents

Volumn 34, Issue 2, 2009, Pages 131-135

  Isnansetyo, Alim ^a   Kamei, Yuto ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Cytotoxicity; In vitro; MRSA; Pseudoalteromonas; Tribromobiphenyl

Indexed keywords

2,2',3 TRIBROMOBIPHENYL 4,4' DICARBOXYLIC ACID; ANTIBIOTIC AGENT; MC 21 B; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; BACILLUS SUBTILIS; BACTERICIDAL ACTIVITY; CANDIDA ALBICANS; CONTROLLED STUDY; CYTOTOXICITY; DRUG PURIFICATION; DRUG STRUCTURE; ENTEROCOCCUS; ENTEROCOCCUS SEROLICIDA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MARINE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOALTEROMONAS; PSEUDOALTEROMONAS PHENOLICA; PSEUDOMONAS AERUGINOSA; PYTHIUM; PYTHIUM PORPHYRAE; STAPHYLOCOCCUS AUREUS; TRICHOPHYTON RUBRUM; VIBRIO ALGINOLYTICUS;

ANTI-BACTERIAL AGENTS; BENZOIC ACIDS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FUNGI; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MOLECULAR STRUCTURE; POLYBROMINATED BIPHENYLS; PSEUDOALTEROMONAS; SPECTRUM ANALYSIS; TIME FACTORS;

EID: 67349159745     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.02.009     Document Type: Article

References (37)

1. Hiramatsu K., Okuma K., Ma X.X., Hori S., and Kapi M. New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community. Curr Opin Infect Dis 15 (2002) 407-413
2. Okuma K., Iwakawa K., Turnidge J.D., Grubb W.B., Bell J.M., O'Brien F.G., et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 40 (2002) 4289-4294
3. Huang H., Flynn N.M., King J.H., Monchaud C., Morita M., and Cohen S.H. Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MRSA infections in Sacramento, California. J Clin Microbiol 44 (2006) 2423-2427
4. Thuong T.C., Tho N.D., Hoa N.T., Minh N.T., Phuong L.V., Tuan T.S., et al. An outbreak of severe infections with community-acquired MRSA carrying the Panton-Valentine leukocidin following vaccination. PLoS ONE 2 (2007) e822
5. Park C., Lee D.-G., Kim S.W., Choi S.-M., Park S.H., Chun H.-S., et al. Predominance of community-associated methicillin-resistant Staphylococcus aureus strains carrying staphylococcal chromosome cassette mec type IVA in South Korea. J Clin Microbiol 45 (2007) 4021-4026
6. Stam-Bolink E.M., Mithoe D., Baas W.H., Arends J.P., and Möller A.V.M. Spread of a methicillin-resistant Staphylococcus aureus ST80 strain in the community of the northern Netherlands. Eur J Clin Microbiol Infect Dis 26 (2007) 723-727
7. Kennedy A.D., Otto M., Braughton K.R., Whitney A.R., Chen L., Mathema B., et al. Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc Natl Acad Sci USA 105 (2008) 1327-1332
8. Larsen A.R., Böcher S., Stegger M., Goering R., Pallesen L.V., and Skov R. Epidemiology of European community-associated methicillin-resistant Staphylococcus aureus clonal complex 80 type IV strains isolated in Denmark from 1993 to 2004. J Clin Microbiol 46 (2008) 62-68
9. Witte W. Antibiotic resistance in Gram-positive bacteria: epidemiological aspects. J Antimicrob Chemother 44 (1999) 1-9
10. Madani T.A. Epidemiology and clinical features of methicillin-resistant Staphylococcus aureus in the university hospital, Jeddah, Saudi Arabia. Can J Infect Dis 13 (2002) 245-250
11. Kerttula A.-M., Lyytikäinen O., Kardén-Lilja M., Ibrahem S., Salmenlinna S., Virolainen A., et al. Nationwide trends in molecular epidemiology of methicillin-resistant Staphylococcus aureus, Finland, 1997-2004. BMC Infect Dis 7 (2007) 94
12. Randrianirina F., Soares J.-L., Ratsima E., Carod J.-F., Combe P., Grosjean P., et al. In vitro activities of 18 antimicrobial agents against Staphylococcus aureus isolates from the Institut Pasteur of Madagascar. Ann Clin Microbiol Antimicrob 6 (2007) 5
13. Delaney J.A.C., Schneider-Lindner V., Brassard P., and Suissa S. Mortality after infection with methicillin-resistant Staphylococcus aureus (MRSA) diagnosed in the community. BMC Med 6 (2008) 2
14. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., and Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40 (1997) 135-136
15. Hanaki H., Labischinski H., Inaba Y., Kondo N., Murakami H., and Hiramatsu K. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob Chemother 42 (1998) 315-320
16. Patersen D.L. Reduced susceptibility of Staphylococcus aureus to vancomycin-a review of current knowledge. Commun Dis Intell 24 (1999) 69-73
17. Neoh H.-M., Hori S., Komatsu M., Oguri T., Takeuchi F., Cui L., et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob 6 (2007) 13
18. Weigel L.M., Donlan R.M., Shin D.H., Jensen B., Clark N.C., McDougal L.K., et al. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 51 (2007) 231-238
19. Mainardi J.L., Shlaes D.M., Goering R.V., Shlaes J.H., Acar J.F., and Goldstein F.W. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 171 (1995) 1646-1650
20. Vaudaux P., Francois P., Berger-Bächi B., and Lew D.P. In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother 47 (2001) 163-170
21. Isnansetyo A., and Kamei Y. Pseudoalteromonas phenolica sp. nov., a novel marine bacterium that produces phenolic anti-methicillin-resistant Staphylococcus aureus substances. Int J Syst Evol Microbiol 53 (2003) 583-588
22. T, against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 47 (2003) 480-488
23. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
24. Woo J.-H., Kitamura E., Myouga H., and Kamei Y. An antifungal protein from the marine bacterium Streptomyces sp. strain AP77 is specific for Pythium porphyrae, a causative agent of red rot disease in Porphyra spp. Appl Environ Microbiol 68 (2003) 2666-2675
25. Aeschliman J.R., and Rybak M.J. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods. Antimicrob Agents Chemother 42 (1998) 2188-2192
26. Entenza J.M., Marchetti O., Glauser M.P., and Moreillon P. Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. Antimicrob Agents Chemother 42 (1998) 1889-1894
27. Harada H., and Kamei Y. Selective cytotoxicity of marine algae extract to several human leukemic cell lines. Cytotechnology 25 (1997) 213-219
28. Verrall M.S., and Warr S.R.C. Scale-up of natural product isolation. In: Cannell R.J.P. (Ed). Natural products isolation (1998), Humana Press, Totowa, NJ 409-424
29. Hebeisen P., Heinze-Krauss I., Angehrn P., Hohl P., Page M.G.P., and Theni R.L. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 45 (2001) 825-836
30. Fung-Tomc J.C., Clark J., Minassian B., Pucci M., Tsai Y.-H., Gradelski E., et al. In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci. Antimicrob Agents Chemother 46 (2002) 971-976
31. Fujimura T., Yamano Y., Yoshida I., Shimada J., and Kuwahara S. In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci. Antimicrob Agents Chemother 47 (2003) 923-931
32. Ueda Y., Kanazawa K., Eguchi K., Takemoto K., Eriguchi Y., and Sunagawa M. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Antimicrob Agents Chemother 49 (2005) 4185-4196
33. Ferrari L., Iavarone L., Braggio S., and Modugno E.D. In vitro and in vivo pharmacokinetics-pharmacodynamics of GV143253A, a novel trinem. Antimicrob Agents Chemother 47 (2003) 770-776
34. Kurazono M., Ida T., Yamada K., Hirai Y., Maruyama T., Shitara E., et al. In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci. Antimicrob Agents Chemother 48 (2004) 2831-2837
35. Ueda Y., and Sunagawa M. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1-methylcarbapenems with potent activities against multiresistant Gram-positive bacteria. Antimicrob Agents Chemother 47 (2003) 2471-2480
36. Denis O., Deplano A., Nonhoff C., Hallin M., Ryck R.D., Vanhoof R., et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother 50 (2006) 2680-2685
37. Pereira E.M., Machado T.B., Leal I.C.R., Jesus D.M., Damaso C.R.A., Pinto A.V., et al. Tabebuia avellanedae naphthoquinones: activity against methicillin-resistant staphylococcal strains, cytotoxic activity and in vivo dermal irritability analysis. Ann Clin Microbiol Antimicrob 5 (2006) 5